Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
about
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceOpportunities for therapeutic antibodies directed at G-protein-coupled receptors.Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.Immunotherapy as an Option for Cancer Treatment.
P2860
Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Development of Engineered T Ce ...... Against Adult T-Cell Leukemia.
@en
type
label
Development of Engineered T Ce ...... Against Adult T-Cell Leukemia.
@en
prefLabel
Development of Engineered T Ce ...... Against Adult T-Cell Leukemia.
@en
P2093
P1476
Development of Engineered T Ce ...... Against Adult T-Cell Leukemia.
@en
P2093
A John Barrett
Fumihiro Ochi
Hiroki Tanaka
Hiroshi Fujiwara
Junichi Mineno
Kazushi Tanimoto
Kiyotaka Kuzushima
Masaki Yasukawa
Nicholas Casey
Sachiko Okamoto
P304
P356
10.1158/1078-0432.CCR-15-2714
P407
P577
2016-04-18T00:00:00Z